In addition, miR-146a is a target for reducing inflammation in patients with CHD because it targets interleukin-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor associated factor 6 (TRAF-6), which leads to inhibition of NF-κB via TLR [155]. The gene discussed is IRAK1; the disease is coronary artery disorder.